Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease
Anne M Fagan, Mark A Mintun, Aarti R Shah, Patricia Aldea, Catherine M Roe, Robert H Mach, Daniel Marcus, John C Morris, David M Holtzman, Anne M Fagan, Mark A Mintun, Aarti R Shah, Patricia Aldea, Catherine M Roe, Robert H Mach, Daniel Marcus, John C Morris, David M Holtzman
Abstract
Alzheimer's disease (AD) pathology is estimated to develop many years before detectable cognitive decline. Fluid and imaging biomarkers may identify people in early symptomatic and even preclinical stages, possibly when potential treatments can best preserve cognitive function. We previously reported that cerebrospinal fluid (CSF) levels of amyloid-beta(42) (Abeta(42)) serve as an excellent marker for brain amyloid as detected by the amyloid tracer, Pittsburgh compound B (PIB). Using data from 189 cognitively normal participants, we now report a positive linear relationship between CSF tau/ptau(181) (primary constituents of neurofibrillary tangles) with the amount of cortical amyloid. We observe a strong inverse relationship of cortical PIB binding with CSF Abeta(42) but not for plasma Abeta species. Some individuals have low CSF Abeta(42) but no cortical PIB binding. Together, these data suggest that changes in brain Abeta(42) metabolism and amyloid formation are early pathogenic events in AD, and that significant disruptions in CSF tau metabolism likely occur after Abeta(42) initially aggregates and increases as amyloid accumulates. These findings have important implications for preclinical AD diagnosis and treatment.
Figures
References
- Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, Tsopelas N, Ziolko S, James J, Snitz B, Houck P, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509–1517.
- Armitage S. An analysis of certain psychological tests used in the evaluation of brain injury. Psych Mono. 1946;60:1–48.
- Bakkour A, Morris J, Dickerson B. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009;72:1048–1055.
- Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease—relation of histologic markers to dementia severity, age, sex, and apoE genotype. Arch Neurol. 1998;55:326–335.
- Blennow K, Meyer GD, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J, et al. Evolution of Abeta42 and Abeta40 Levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging. 2009;13:205–208.
- Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–357.
- Cairns N, Ikonomovic M, Benzinger T, Storandt M, Fagan A, Shah A, Reinwald L, Carter D, Felton A, Holtzman D, et al. PiB-PET detection of cerebral Aβ may lag clinical, cognitive, and CSF markers of Alzheimer's disease: a case report. Arch Neurol. 2009 (in press)
- Cirrito J, May P, O'Dell M, Taylor J, Parsadanian M, Cramer J, Audia J, Nissen J, Bales K, Paul S, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci. 2003;23:8844–8853.
- Craig-Schapiro R, Fagan A, Holtzman D. Biomarkers of Alzheimer's disease. Neurobiol Dis. 2008;35:128–140.
- Dickerson B, Bakkour A, Salat D, Feczko E, Pacheco J, Greve D, Grodstein F, Wright C, Blacker D, Rosas H, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497–510.
- Fagan A, Head D, Shah A, Marcus D, Mintun M, Morris J, Holtzman D. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:175–183.
- Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, Shah A, LaRossa G, Spinner M, Klunk W, Mathis C, et al. Inverse relation between in vivo amyloid imaging load and CSF Aβ42 in humans. Ann Neurol. 2006;59:512–519.
- Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D. Cerebrospinal fluid tau/Aβ42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343–349.
- Fukumoto H, Tennis M, Locascio J, Hyman B, Growdon J, Irizarry M. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958–964.
- Gomez-Isla T, Price J, McKeel D, Morris J, Growdon J, Hyman B. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491–4500.
- Goodglass H, Kaplan E. Boston Naming Test scoring booklet. Philadelphia: Lea & Febiger; 1983.
- Gotz J, Chen F, Dorpe JV, Nitsch R. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491–1495.
- Graff-Radford N, Crook J, Lucas J, Boeve B, Knopman D, Ivnik R, Smith G, Younkin L, Petersen R, Younkin S. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354–362.
- Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;3:900–903.
- Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228–234.
- Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2008 in press, doi: .
- Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in “normal” aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168–1174.
- Jack C, Lowe V, Weigand S, Wiste H, Senjem M, Knopman D, Shiung M, Gunter J, Boeve B, Kemp B, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355–1365.
- Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, Bergström M, Savitcheva I, Huang G-F, Estrada S, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–319.
- Lachno D, Vanderstichele H, Groote GD, Kostanjevecki V, Meyer GD, Siemers E, Willey M, Bourdage J, Konrad R, Dean R. The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the Inno-Bia Plasma Abeta Forms Multiplex Assay. J Nutr Health Aging. 2009;13:220–225.
- Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol. 2009 (in press), PMID:19664622.
- Lewis J, Dickson D, Lin W, Chisholm L, A AAC, Jones G, Yen S, Sahara N, Skipper L, Yager D, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487–1491.
- Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G, Kaye J, Raskind M, Zhang J, Peskind E, et al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631–639.
- Logan J, Fowler J, Volkow N, Wang G, Ding Y, Alexoff D. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834–840.
- Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, Wekstein D. Neuropathologic substrate of Mild Cognitive Impairment. Arch Neurol. 2006;63:38–46.
- Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S, Van der Flier WM, Blankenstein M, Ewers M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385–393.
- Mehta P, Pirttila T. Increased cerebrospinal fluid Abeta38/Abeta42 ratio in Alzheimer's disease. Neurodegener Dis. 2005;2:242–245.
- Mintun M, LaRossa G, Sheline Y, Dence C, Lee S-Y, Mach R, Klunk W, Mathis C, DeKosky S, Morris J. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–452.
- Morris J, McKeel D, Fulling K, Torack R, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol. 1988;24:17–22.
- Morris J, Price J. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease. J Mol Neurosci. 2001;17:101–118.
- Morris J, Roe C, Grant E, Head D, Storandt M, Goate A, Fagan A, Holtzman D, Mintun M. PIB imaging predicts progression from cognitively normal to symptomatic Alzheimer's disease. Arch Neurol. 2009 (in press)
- Morris JC. The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology. 1993;43:2412–2414.
- Oddo S, Caccamo A, Kitazawa M, Tseng B, LaFerla F. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003a;24:1063–1070.
- Oddo S, Caccamo A, Shepherd J, Murphy M, Golde T, Kayed R, Metherate R, Mattson M, Akbari Y, LaFerla F. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aß and synaptic dysfunction. Neuron. 2003b;39:409–421.
- Price J, Ko A, Wade M, Tsou S, McKeel D, Morris J. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease. Arch Neurol. 2001;58:1395–1402.
- Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol. 1999;45:358–368.
- Rafii M, Aisen P. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 (in press)
- Salloway S, Mintzer J, Weiner M, Cummings J. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008;4:65–79.
- Schoonenboom N, Mulder C, Kamp GV, Mehta S, Scheltens P, Blankenstein M, Mehta P. Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol. 2005;58:139–142.
- Schupf N, Tang M, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA. 2008;105:14052–14057.
- Snider B, Fagan A, Roe C, Shah A, Grant E, Xiong C, Morris J, Holtzman D. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 2009;66:638–645.
- Sunderland T, Mirza N, Putnam K, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, et al. Cerebrospinal fluid beta-amyloid -42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry. 2004;56:670–676.
- Welge V, Fiege O, Lewczul P, Mollenhauer B, Esselmann H, Klafki H-W, Wolf S, Trenkwalder C, Otto M, Kornhuber J, et al. Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm. 2009;116:203–212.
Source: PubMed